In 1800 patients with diabetes and multivessel disease undergoing PCI, ticagrelor failed non-inferiority vs prasugrel (each with aspirin) for 1-year death, MI, stroke or major bleeding (16.6% vs 14.2%).
RCTn = 1,800
Bangalore et al. Ticagrelor vs Prasugrel in Patients With Diabetes and Multivessel Coronary Artery Disease: The TUXEDO-2 Randomized Clinical Trial